AIC316 is a novel anti-HSV drug in clinical phase 2 testing currently.

AIC316 is a novel anti-HSV drug in clinical phase 2 testing currently . AiCuris task and scientist innovator Dr. Alexander Birkmann will give a synopsis on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine disease model and Phase 1 pharmacokinetic data which demonstrate that the predicted efficacious concentrations of AIC316 will be quickly achieved in humans. The oral presentation will be held during Plenary Program 5 on ‘Antiviral Resistance’ scheduled for Monday, November 8, 2010, at 14:40 hrs, NH Grand Resort Krasnapolsky, Amsterdam.

And AlertNet reviews that UNICEF has warned that thousands of kids in Chad are at risk of dying from malnutrition and has called for more money for aid activities in the country . This article was reprinted from with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.. Aid organizations warn April’s steep increases in grain prices can affect Sahel nations during lean season ‘Unexpectedly sharp cost rises in April for local cereals like millet, rice, and maize in parts of Mali, Burkina Faso, Niger, and Chad mean many vulnerable people in the drought-hit Sahel could find it even harder to obtain enough to consume,’ IRIN reviews.